hrp0097fc6.3 | Pituitary, neuroendocrinology and puberty 1 | ESPE2023

Is the 24-hour urinary gonadotropin assay an effective diagnostic tool in central precocious puberty? A retrospective study of threshold setting and validation in two cohorts.

Janot Clément , Perrin Pauline , Bretones Patricia , Malburet-Testori Sarah , Perge Kevin , Raverot Véronique , Robert Zoé , Roucher-Boulez Florence , Villanueva Carine , Nicolino Marc , Plotton Ingrid

Background and Aims: Central Precocious Puberty (CPP) caused by the early activation of the hypothalamic-pituitary-gonadal axis is a rare affection that occurs in 0.2% in girls. Clinical signs are suggestive and LHRH-test could be sometimes difficult to use and not always contributive. Gonadotropin assay in twenty-four hours-urinary collection could be an interesting option. The present work intended to evaluate the diagnostic interest of 24-hour urinary gonad...

hrp0097p1-8 | Adrenals and HPA Axis | ESPE2023

Congenital Adrenal Hyperplasia (CAH): Situation and Possibility to Develop a Newborn Screening in Indonesia -- An Exploratory Study

Pulungan Aman , Armstrong Kate , Fadiana Ghaisani , Idaayen Fatima , Waladhiyaputri Vahira , Patricia Chandra Angelina , Fadia Ratnasari Amajida , Arnetta Puteri Helena , Utari Agustini

Introduction: Indonesia, an archipelago with approximately 17,000 islands and 34 provinces has around 4.8 million babies born annually, yet only 2-3% undergo newborn screening (NBS) resulting in high preventable disease burdens. Currently, the country only has 1 newborn screening project which will be relaunched and aimed to cover 30-40% of babies. Health policy plays a huge role in determining the day-to-day lives of children, families, and health professiona...

hrp0097p2-131 | Diabetes and Insulin | ESPE2023

Ketoacidosis in the newborn as a presentation of IPEX Syndrome

Pino Consuelo , Pizarro Hugo , Contreras Andy , Karime Rumie Hana , Godoy Claudia , Grob Francisca , Naranjo Carolina , Lacourt Patricia , Bassaure Javiera , Mayol Cristina , Garcia Angelica , Postigo Javiera , Jara Mirta

Introduction: IPEX syndrome is a syndrome characterized by the following triad: immune dysregulation, polyendocrinopathy and X-linked enteropathy. It is produced by a variant in the FOXP3 gene. It is a rare disease with poor prognosis.Clinical case: We are reporting the case of a boy, 2nd child of non-consanguineous parents, normal pregnancy. Born at 39 weeks of gestational age, birth weight 2985 grams and length 49 cent...

hrp0097p2-154 | Multisystem Endocrine Disorders | ESPE2023

Hypoglycemia in a 9-month-old infant due to hyperinsulinism by ABCC8 variant

Pino Consuelo , Pizarro Hugo , Contreras Andy , Mayol Cristina , Karime Rumie Hana , Lacourt Patricia , Bassaure Javiera , Garcia Angelica , Postigo Javiera , Jara Mirta

Introduction: Hypoglycemia due to Congenital hyperinsulinism is a phenotypically heterogeneous disease. Depending on the cause it is most frequently seen in the neonatal period but it can present later in life, with risk of neurological complications in the event of late diagnoses.Clinical Case: Patient with a normal perinatal history, born at 40 weeks, weight 3600 grams and 50.5 centimeters of length. Because caf&eacute...

hrp0086rfc5.5 | Management of Disorders of Insulin Secretion | ESPE2016

The Efficacy of Insulin Degludec in Children and Adolescents with Type 1 Diabetes

Bruzzi Patrizia , Maltoni Giulio , Predieri Barbara , Zucchini Stefano , Iughetti Lorenzo

Background: Insulin degludec (IDeg; Tresiba®) is a novel basal insulin with an ultra-long, flat and stable action profile. In adults, it provides a more consistent glucose-lowering effect and lower rates of hypoglycaemia than glargine (IGlar). Data on children and adolescents are scarce.Objective and hypotheses: To assess efficacy of IDeg among children and adolescents affected by type 1 diabetes (T1DM) previously on IGlar.Met...

hrp0084fc12.1 | Obesity - Clinical | ESPE2015

Evaluation of Cardiovascular Risk in Childhood: Data from a Survey of Dyslipidaemic Children

Bruzzi Patrizia , Colombini Giulia , Lucaccioni Laura , Predieri Barbara , Iughetti Lorenzo

Background: Dyslipidaemia is a well-known risk factor in developing cardiovascular disease (CVD) already in childhood.Objective and hypotheses: To investigate the clustering of cardiovascular risk-factors (anthropometric parameters, blood pressure and metabolic abnormalities) in different type of dyslipidaemia in children and adolescents.Method: All the subjects aging 2–18 years referred for dyslipidaemia to our endocrine outp...

hrp0084p3-629 | Autoimmune | ESPE2015

Early-onset Type 1 Diabetes and Multiorgan Autoimmunity in a Girl with Partial Monosomy 2q and Trisomy 10p

Bizzarri Carla , Matteoli Maria Cristina , Patera Ippolita Patrizia , Cappa Marco

Background: Genes in the HLA region confer about 50% of the genetic risk of type 1 diabetes (T1DM). More than 40 different genes give a minor contribution to T1DM risk, some of them are related to the immune function.Case presentation: A girl was referred at the age of 9 months with severe ketoacidosis in T1DM at onset. Anti-insulin autoantibodies were positive. She was the only daughter of unrelated Caucasian parents, born at term by vaginal delivery. T...

hrp0097p1-51 | Fat, Metabolism and Obesity | ESPE2023

GLP1 agonists improve glycaemic dysregulation, satiety levels and quality of life in adolescents with obesity

Apperley Louise , Parkinson Jennifer , Senniappan Senthil , Patrizia Bruzzi

Introduction: GLP-1 receptor agonists (GLP1A) have been shown to be effective in achieving weight loss in adolescents with obesity and improve glycaemic control in type 2 diabetes mellitus (T2DM). We aimed to investigate the glycaemic alterations and satiety levels in patients treated with the GLP1A, liraglutide. To the best of our knowledge, this is the first study of its kind.Methods: In total, 22 patients managed in a...

hrp0095rfc6.4 | Sex Development and Gonads | ESPE2022

Sertoli cell dysfunction at diagnosis in children with haematological malignancies

Lopez Dacal Jimena , Prada Silvina , Gabriela Ropelato Maria , Gabriela Ballerini Maria , Eugenia Rodriguez Maria , E. Gutierrez Marcela , Soria Marcela , Morán Lorena , Ferraro Cristina , Bedecarrás Patricia , Drelichman Guillermo , Aversa Luis , Bergadá Ignacio , A. Rey Rodolfo , P. Grinspon Romina

Aim: To determine Sertoli cell function at diagnosis and after 3 months of chemotherapy.Methods: A prospective cohort study was performed including children with acute lymphoblastic leukaemia, acute myeloid leukaemia, or non-Hodgkin lymphoma. Serum levels of AMH were evaluated at diagnosis and after 3 months during chemotherapy. Results were analysed as standard deviation scores according to pubertal stage and expressed ...

hrp0095rfc10.4 | GH and IGFs | ESPE2022

Recombinant PAPP-A2 induces sex-specific increases in body weight and length and changes in bone microstructure in adolescent mice with longitudinal growth reduction induced by Pappa2 deletion

del Mar Fernández-Arjona María , Rubio Leticia , López-Gambero Antonio , Rivera Patricia , Vargas Antonio , Rodríguez de Fonseca Fernando , A. Chowen Julie , Argente Jesús , Suárez Juan

Deficiency of pregnancy-associated plasma protein-A2 (PAPP-A2), a protease that regulates IGF-1 availability, causes postnatal growth failure and changes in bone size and density in humans and mice. The present study aimed to determine the effects of daily administration (from PND5 to PND35) of recombinant murine (rm) PAPP-A2, in comparison to rmGH and rmIGF1, on mouse auxology and bone microarchitecture in homozygous Pappa2 knock-out (ko/ko) mice of both sexes. Hormone treatm...